Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12.
The two abstracts presented were titled 'The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis having solid tumors; implications for treating the LM tumor with anti-HER2 therapy', and 'Circulating tumor cell analysis from the cerebrospinal fluid informs early diagnosis, treatment and prognosis in leptomeningeal carcinomatosis (LMC)'.
The abstracts were presented by United Counsel for Neurologic Subspecialties-certified neuro-oncologist at Northwestern University, Dr. Priya U. Kumthekar and director of Neuro-Oncology at the University of California, San Diego Dr. David Piccioni.
Dr. Kumthekar is the principal investigator of Biocept’s ongoing FORESEE clinical trial, which is evaluating the performance of CNSide for leptomeningeal metastasis (LM) and assessing the impact of CNSide on treatment decisions made by physicians, the company noted.
“While patients with leptomeningeal metastasis (LM) have limited treatment options, select patients may benefit from targeted therapies,” Dr. Kumthekar said in a statement.
“Using CNSide in patients with solid tumors and LM to detect HER2 amplification could provide valuable information in treatment decision making.”
Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie